Menu

Verhaagen Group

ERA-NET grant for research on spinal cord repair

The neuroregeneration group led by joost Verhaagen was awarded with a ERA-NET grant of 225.000 euros for his research on spinal cord repair, entitled AxonRepair. The project is aimed on releasing the neuron-intrinsic brake on axon regeneration.

Spinal cord injury (SCI) leads to permanent disability and is a significant clinical problem with 130.000 new cases/year worldwide. Following SCI long axon tracts fail to regenerate. This is the primary reason for the sustained loss of bodily functions.

AxonRepair

AxonRepair aims to develop a strategy to promote long-distance axon regeneration and functional recovery after SCI by reprogramming neurons into a regenerative state and by overcoming the axon transport block that is a barrier to axon regeneration. Joost Verhaagen: “In AxonRepair we bring together world-class experts on the transcriptional control of axon regeneration, axon transport and therapeutic gene delivery. We already have identified factors that promote CNS axon regeneration and modest sensorimotor recovery in animal models of SCI. We now seek to combine these factors to deliver greater axon regeneration and clinically significant functional recovery. We will use clinically translatable adeno-associated vector-based gene delivery, novel techniques to quantify axon trajectories in cleared spinal tissue and innovative, automated methods for assessing dexterity in rats”.

Work package (WP) 1 aims to reprogram neurons into a regenerative state by testing the effect of combinatorial delivery of key transcription factors identified in our collective’s discovery pipelines. WP 2 aims to restore axonal transport of growth-related receptors (integrins) to injured spinal axons. WP 3 aims to provide novel mechanistic insight into how interventions at the transcriptional and axon transport level work and whether these interventions act synergistically in rat models of SCI. At completion of the project Verhaagen expects to have developed a method to release the brake on axon regeneration. The participation of the world-leading gene therapy company uniQure ensures that newly generated know-how will be exploited rapidly by entering into a co-development agreement and/or intellectual property strategy.

Share

Verhaagen Group

This laboratory performs basic and translational research with the aim to advance the field of restorative neuroscience and neurology. We focus on the cellular and molecular mechanisms that underlie degeneration, regeneration and plasticity of the central and peripheral nervous system. A significant portion of research is dedicated to the identification of novel genes and molecular pathways that affect the capacity of the nervous system to regenerate. Genomics, bioinformatics and high-throughput functional screening are key components of our research strategy and gene therapy based on advanced viral vector technology is applied to validate the therapeutic efficacy of molecular targets in clinically relevant animal models of neurodegeneration and repair. The ultimate goal of the Laboratory for Neuroregeneration is to develop novel therapeutic strategies to promote regeneration and plasticity of injured axons.

Read more